Stay updated on PI3K/Akt Suppression vs MK-3475 in Glioblastoma Clinical Trial

Sign up to get notified when there's something new on the PI3K/Akt Suppression vs MK-3475 in Glioblastoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the PI3K/Akt Suppression vs MK-3475 in Glioblastoma Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:27:48.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update in the evaluation of the effectiveness of treatment for Glioblastoma / Gliosarcoma through the suppression of the PI3K/Akt pathway compared to MK-3475 (Pembrolizumab) in a Phase IIb trial.
    Difference
    0.1%
    Check dated 2024-06-06T14:24:22.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value '6' has been updated to 'The U.S. government does not review or approve the safety and science of all studies listed on this website. Read our full disclaimer for details. Unknown status Evaluation Of The Treatment Effectiveness Of Glioblastoma /​ Gliosarcoma Through The Suppression Of The PI3K/​Akt Pathway In Compared With MK-3475 ClinicalTrials.gov ID NCT02430363 Sponsor Medical Research Council Information provided by Ms. Jann Lee, Medical Research Council (Responsible Party) Last Update Posted 2016-02-24 Expa.' This change likely pertains to medical and healthcare-related publications and documentation.
    Difference
    100%
    Check dated 2024-05-22T20:29:46.000Z thumbnail image
  8. Check
    26 days ago
    Change Detected
    Summary
    The value 'Expa' has recently changed to an unknown status. This change may indicate a shift in the status or information related to the treatment effectiveness study of Glioblastoma/Gliosarcoma through the suppression of the PI3K/Akt pathway.
    Difference
    77%
    Check dated 2024-05-21T12:39:57.000Z thumbnail image
  9. Check
    46 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:31:41.000Z thumbnail image

Stay in the know with updates to PI3K/Akt Suppression vs MK-3475 in Glioblastoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the PI3K/Akt Suppression vs MK-3475 in Glioblastoma Clinical Trial page.